Greg Pyszczymuka
Equibles does not estimate personal net worth.
Get an email with a short summary when Aytu Biopharma, Inc publishes a filing, an earnings call transcript or a press release.
Get AYTU alertsAbout Greg Pyszczymuka
The proxy statement of Aytu Biopharma, Inc reports total compensation of $558,918 for Greg Pyszczymuka in fiscal 2026, including a base salary of $434,300. Disclosed compensation is on record for 4 fiscal years. Aytu Biopharma, Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Aytu Biopharma, Inc includes Joshua R. Disbrow (CEO and Board Member), John A. Donofrio, Jr. (Chairman), Gregory A. Gould (CFO) and 7 others.
Affiliation history
-
Aytu Biopharma, Inc (AYTU)
Proxy statement
CurrentStart not stated–present
Last confirmed October 22, 2026
Company network
Leadership on record at Aytu Biopharma, Inc
- Joshua R. Disbrow CEO, Board Member
- John A. Donofrio, Jr. Chairman
- Gregory A. Gould CFO
- Ryan Selhorn CFO
- Christopher Brooke COO
- Abhinav Jain Board Member
- Beth Hecht Board Member
- Beth P. Hecht Board Member
- Carl C. Dockery Board Member
- Gerald McLaughlin Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2026 | Aytu Biopharma, Inc (AYTU) | Chief Commercial Officer since January 2022 | $434,300 | $558,918 |
| 2025 | Aytu Biopharma, Inc (AYTU) | Chief Commercial Officer since January 2022 | $401,403 | $522,076 |
| 2024 | Aytu Biopharma, Inc (AYTU) | Chief Commercial Officer since January 2022 | $389,423 | $516,301 |
| 2023 | Aytu Biopharma, Inc (AYTU) | Chief Commercial Officer since January 2022 | $375,000 | $540,046 |
Recent activity
No call appearances or filed executive changes recorded yet.